查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1820442

2025 年至 2033 年臨床前 CRO 市場規模、佔有率、趨勢及按服務、最終用途和地區分類的預測

Preclinical CRO Market Size, Share, Trends, and Forecast by Service, End Use, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球臨床前CRO市場規模為64億美元。展望未來， IMARC Group估計，到2033年，市場規模將達到113億美元，2025年至2033年的複合年成長率為6.5%。北美目前佔據市場主導地位，2024年的市佔率將超過47.5%。研發支出不斷成長、監管環境日益複雜、企業日益注重核心競爭力以及專科治療領域的最新進展是推動該地區市場發展的主要因素。

臨床前合約研究組織 (CRO) 市場成長的主要驅動力是對外包研發 (R&D) 的需求不斷成長，以簡化藥物發現並節省成本。製藥和生物技術公司已經開始相當程度地依賴 CRO 的專業知識、先進技術和更全面的臨床前測試服務。除此之外，更廣泛的生物製藥研究、對創新療法的更多投資以及需要滿足的更嚴格的監管要求正在推動市場成長。此外，慢性病盛行率的上升和藥物開發速度的加快導致對臨床前 CRO 服務的需求增加。推動臨床前 CRO 市場成長的另一個因素是持續的技術進步，例如人工智慧 (AI) 驅動的藥物發現和更好的實驗室工作，使與 CRO 的合作在全球範圍內更加高效和有吸引力。

美國正在興起一個巨大的市場，佔據約93.7%的市場。製藥和生物技術公司擴大將臨床前研究的各個環節外包給合約研究組織（CRO），以節省成本並加快藥物開發速度。越來越多的慢性病需要新的治療方案來治療，這也進一步刺激了市場對臨床前合約研究組織（CRO）的需求。此外，藥物開發的複雜性不斷增加以及監管要求越來越嚴格，迫使公司尋求CRO的專業知識。根據美國疾病管制與預防中心（CDC）的統計數據，美國每十個成年人中就有六人患有癌症、心臟病或糖尿病等慢性疾病。慢性病是美國的頭號殺手。心臟病和癌症合計佔總死亡人數的近40%。慢性病發病率的上升對新療法的需求日益迫切，這正在促進市場的成長。

臨床前CRO市場趨勢：

研發活動不斷增加

製藥和生物技術行業不斷升級的研發活動正在推動臨床前 CRO 市場佔有率的成長。此外，現代藥物開發過程非常複雜，需要經過漫長的臨床前測試過程以確保新藥的安全性和有效性。研究人員必須遵循美國食品藥物管理局 (FDA) 的良好實驗室規範 (GLP) 來規範臨床前研究的醫療產品開發。此外，據報道，印度的臨床前 CRO 市場正在快速成長，2023 年的價值為 1.833 億美元，到 2030 年的複合年成長率將達到 11.4%。隨著研究活動的增加和基礎設施的發達，包括全球外包需求，印度已成為臨床前研究的主要目的地。 Syngene 和 Jubilant Biosys 是毒理學、安全藥理學和生物分析服務的創新者。此外，對於製藥公司來說，將臨床前研發活動外包給 CRO 比自己進行更具成本效益。 CRO 擁有專業知識和基礎設施，可以幫助簡化藥物開發流程並降低成本。例如，2024 年 1 月，美國國家轉化科學促進中心 (NCATS) 與其他 NIH 研究所和中心合作開發了一個臨床前研究工具箱。這些工具箱包括《檢測指導手冊》、《化合物管理》、《NCATS 藥物庫》、《PubChem》、《探針》、《表現型藥物發現資源》和《BioPlanet》。

複雜的監管環境

製藥和生物技術產業複雜的監管環境是影響臨床前 CRO 市場前景的重要因素。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構要求進行廣泛的臨床前測試，以證明新藥的安全性和有效性。此外，例如，美國國家轉化科學促進中心與學術界、工業界和患者權益團體合作，使 45 多種新藥進入臨床試驗階段。據他們介紹，一種新藥從實驗室到藥櫃的整個過程可能需要長達 15 年的時間。這導致對臨床前 CRO 服務的需求增加，以確保符合監管要求。此外，臨床試驗的全球化要求製藥公司了解各國複雜的監管環境。具有經驗並熟悉國際監管要求的臨床前 CRO 可以幫助公司克服這些困難。例如，美國疾病管制與預防中心 (CDC) 聲稱，實驗室研究需要 10 到 15 年才能準備好疫苗，研究人員必須向 FDA 提交包含疫苗所有資訊的試驗性新藥申請。 FDA 的生物製品評估與研究中心負責監管美國疫苗的使用。

藥物開發成本不斷增加

藥物開發成本的上升進一步推高了臨床前CRO市場的收入。新藥研發是一個非常複雜且耗時的過程。在藥物開發過程中，大量的研究和測試至關重要。因此，這種複雜性導致了臨床前研究的高成本。此外，為了確定新藥的安全性和有效性，EMA和FDA都要求進行完整的臨床前測試。滿足這些監管規定成本高。藥物開發本身就存在風險，儘管投入了大量資金，但仍有許多藥物未能進入市場。根據美國生物化學與分子生物學學會會員雜誌報道，開發一種成功的藥物需要10到15年的時間。研究人員發現，40%到50%的失敗案例是因為藥物無法對人體產生預期的效果。大約10%到15%的失敗是由於藥物動力學特性設計不當。同時，大約30%的失敗是由於毒性/毒性/不良反應無法控制。根據臨床前 CRO 市場預測，主要公司可以透過提供與臨床前研究相關的專業知識來緩解這種危險，從而更好地指導他們選擇要考慮的藥物。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球臨床前CRO市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依服務

  • 生物分析和 DMPK 研究
  • 毒理學測試
  • 其他

第 7 章：市場區隔：最終用途別

  • 生物製藥公司
  • 政府和學術機構
  • 醫療器材公司

第8章：市場區隔：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章：SWOT分析

第 10 章：價值鏈分析

第 11 章：波特五力分析

第 12 章：價格分析

第 13 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Charles River Laboratories Inc.
    • Covance Inc. (Laboratory Corporation of America Holdings)
    • Eurofins Scientific
    • ICON Plc
    • MD Biosciences Inc. (MLM Medical Labs)
    • Medpace
    • Parexel International Corporation
    • PPD Inc.
    • Wuxi AppTec
Product Code: SR112025A3715

The global preclinical CRO market size was valued at USD 6.4 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 11.3 Billion by 2033, exhibiting a CAGR of 6.5% from 2025-2033. North America currently dominates the market, holding a market share of over 47.5% in 2024. The growing expenditure on research and development (R&D) activities, the rising complexity of the regulatory environment, the increasing focus on core competencies among companies, and recent advancements in specialized treatments are some of the major factors propelling the market in the region.

The main driving force behind the growth of the preclinical contract research organization (CRO) market is the growing demand for outsourcing research and development (R&D) to streamline the discovery of drugs and save costs. Pharmaceutical and biotechnological companies have started taking considerable dependence on CRO's specialized expertise, advanced technology, and more inclusive preclinical testing services. Besides this, more extensive biopharmaceutical research, higher investments in innovative therapies, and stringent regulatory requirements that need to be fulfilled are impelling the market growth. Moreover, the escalating prevalence of chronic diseases and faster pace of drug development have led to the increased demand for preclinical CRO services. Another factor driving preclinical CRO market growth is the continuous technological progress such as artificial intelligence (AI)-driven drug discovery, and better laboratory work making the partnership with CRO more efficient and attractive worldwide.

A massive market is emerging in the United States, holding approximately 93.7% market share. Pharmaceutical and biotechnological companies are outsourcing all aspects of preclinical research increasingly to CROs just in order to save money on costs and accelerate the speed of drug development. A higher incidence of chronic diseases to be treated with new treatment options is also fueling further market demand for preclinical CROs. Along with this, the rising complexity of drug development and stricter regulatory requirements are forcing companies to seek specialized expertise from CROs. According to statistics from the Centers for Disease Control and Prevention (CDC), six in ten adults in the U.S. live with a chronic disease such as cancer, heart disease, or diabetes. Chronic diseases form the top killer in the United States. Heart disease and cancer combined take almost 40% of the total deaths. The growing rate of chronic diseases calls for a requirement of new therapies, which is strengthening the market growth.

Preclinical CRO Market Trends:

Rising Research and Development Activities

The escalating R&D activities in the pharmaceutical and biotechnology industries are driving the preclinical CRO market share. Further, the modern drug development process is complex and demands a lengthy preclinical testing process for the safety and efficacy of new drugs. Researchers must use Good Laboratory Practice (GLP) defined in U.S. Food and Drug Administration (FDA) rules for regulation of medical product development for preclinical studies. Moreover, according to reports, India's preclinical CRO market, valued at USD 183.3 Million in 2023, is growing rapidly, driven by a CAGR of 11.4% through 2030. With increasing research activities and developed infrastructure, including global outsourcing demand, Indian is a prime destination in preclinical research. Innovators in toxicology, safety pharmacology, and bioanalytical services are Syngene and Jubilant Biosys. In addition, outsourcing preclinical R&D activities to CROs is more cost-effective for the pharmaceutical companies as compared to their in-house performance. CROs have specialized expertise and infrastructures that can assist in streamlining the process of drug development and making it less expensive. In January 2024, for example, the National Center of Advancing Translational Sciences developed a preclinical research toolbox in collaboration with other NIH institutes and centers. These include Assay Guidance Manual, Compound Management, NCATS Pharmaceutical Collection, PubChem, Probes, Phenotypic Drug Discovery Resource, and BioPlanet.

Complex Regulatory Environment

The complex regulatory environment in the pharmaceutical and biotechnology industries is a significant factor adding to the preclinical CRO market outlook. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require extensive preclinical testing to demonstrate the safety and efficacy of new drugs. Moreover, for instance, the National Center for Advancing Translational Sciences partnered with academia, industry, and patient advocacy groups to enable more than 45 novel drugs to move into clinical trials. According to them, a new drug's journey from the lab to the medicine cabinet can take up to 15 years. This has led to an increased demand for preclinical CRO services to ensure compliance with regulatory requirements. In addition, the globalization of clinical trials requires pharmaceutical companies to understand the intricate regulatory landscape in various countries. Preclinical CROs with experience and familiarity with international regulatory requirements can enable them to assist companies in conquering these difficulties. For example, the Centers for Disease Control and Prevention claim that laboratory research takes 10 to 15 years to get vaccines ready, and researchers have to apply to the FDA with an investigational new drug application that includes all information on the vaccine. The FDA's Center for Biologics Evaluation and Research regulates the use of vaccines in the United States.

Increasing Cost of Drug Development

The rising cost of drug development is further pushing the revenue of the preclinical CRO market. It is a very complex and time-consuming process to discover new drugs. Extensive research and testing are essential in drug development. Thus, such complexity contributes to the high cost that goes with the performance of preclinical studies. Additionally, with respect to establishing the safety and efficacy of new drugs, both the EMA and the FDA require complete preclinical testing. Meeting these regulatory provisions is costly. Drug development is inherently risky, with many drugs failing to reach the market despite significant investments. According to Member Magazine of the American Society for Biochemistry and Molecular Biology, it takes 10 to 15 years to develop one successful drug. Researchers discovered that the drug's inability to have the desired impact in humans was between 40% and 50% of failures. About 10% to 15% resulted from poorly designed pharmacokinetic characteristics. Meanwhile, about 30% resulted from being uncontrollably toxic/toxicity/adverse. According to preclinical CRO market forecast, key companies can ease such dangers by providing preclinical research-related expertise that can guide them better in choosing the drugs to consider.

Preclinical CRO Industry Segmentation:

Analysis by Service:

  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Others

Toxicology testing is the largest segment that commands around 51.6% of the market share in 2024, mainly due to the significant role that toxicology studies play in providing assurance regarding the safety of drugs and good compliance with high regulatory standards. The increasing demand for innovative therapies, as well as the complexity of drug formulations, has compelled pharmaceutical companies to conduct extensive toxicology testing. The in-vivo and in-vitro testing, genotoxicity studies, along with, carcinogenicity assessments are all popular services with respect to safety during early drug development. The increasing incidence of chronic diseases and increased investment in biopharmaceutical research form an underpinning driver for the demand for such services and emphasize toxicology testing as a core component of the preclinical CRO market.

Analysis by End Use:

  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies

Biopharmaceutical companies are the largest end-users of preclinical CRO services in 2024, taking about 81.0% of the market share. This is due to the biologics and targeted therapies, which come along with heavy preclinical research undertaken on them to ascertain efficacy and safety. These firms believe in the best use of available preclinical CRO services in meeting advanced testing capabilities, making the research more effective, and standing rigorous regulatory requirements. Another factor propelling investments in drug development from biopharmaceutical companies is the rising incidence of chronic diseases, combined with increased demand for personalized medicine. CRO outsourcing also enables such companies to decrease operational costs and speed up time-to-market for innovative therapies, making these companies the principal drivers of growth in the preclinical CRO market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America holds the largest chunk of the preclinical CRO market in 2024, with around 47.5% of the world's share. The reasons behind this can be attributed to the strength of the pharmaceutical and biotechnology industries, higher research grants, and an established regulatory framework within that region. With cutting-edge health infrastructure, significant chronic disease prevalence, and majorly research and innovation-based drug development within this region, the US contributes the most in bringing forward growth. In fact, biopharmaceutical firms are outsourcing more than before to save on operational cost and time while managing a research pipeline. Furthermore, higher penetration of more advanced technologies is in AI-driven drug discovery, laboratory automation, and the further strengthening of North America's presence as a major hub of preclinical CRO activity.

Key Regional Takeaways:

United States Preclinical CRO Market Analysis

The adoption of preclinical research services is significantly advancing the United States' biomedical and pharmaceutical sectors by allowing precise drug development and regulatory compliance. For example, the U.S. pharmaceutical industry, generating over USD 550 Billion in 2021 and employing 1.3 Million people, is driving the adoption of preclinical CRO through robust R&D investments and its dominant global market position. By utilizing cutting-edge technologies such as AI-driven drug modeling and advanced imaging systems, the U.S. is best positioned to lead in healthcare innovations. The research on personalized medicine in California and the breakthroughs in oncology in Massachusetts are examples of such leadership. States like Texas and North Carolina are also emerging as prominent hubs, benefiting from streamlined preclinical services that reduce development timelines and costs. These innovations bolster competitiveness on a global scale, attracting investments from countries including Germany and Japan. The U.S. stands out for its ability to integrate advancements with localized expertise, such as leveraging robust research facilities in academic centers. This strategic adoption enhances the country's role in addressing complex health challenges while maintaining its status as a global powerhouse in preclinical development.

Europe Preclinical CRO Market Analysis

Europe holds a prominent position in the preclinical Contract Research Organization (CRO) market, driven by its advanced healthcare infrastructure and a focus on biotechnological and pharmaceutical innovation. Countries such as Germany, the United Kingdom, and France are leading contributors, with a strong presence of global biopharma companies and research institutions. The region benefits from robust regulatory frameworks and streamlined drug approval processes, which make it an attractive destination for preclinical research. For instance, Germany's National Pharma Strategy aims to reverse its declining share in global clinical trials, down to 3.9% in 2021, by fostering faster approvals, reducing bureaucracy, and incentivizing local research. These reforms, including the Medical Research Act, are driving preclinical CRO adoption to support pharmaceutical innovation and competitiveness. Key advancements, such as the integration of AI in drug discovery and precision medicine studies, are transforming the preclinical landscape in Europe. For instance, Germany's thriving pharmaceutical sector supports extensive preclinical toxicology and pharmacokinetics research, while the UK fosters innovation through partnerships between CROs and academic centers. Locations such as Switzerland and Belgium further enhance the region's capabilities, offering specialized services like disease modeling and high-throughput screening. With significant investments in biopharma R&D, Europe is addressing critical unmet medical needs, reinforcing its role as a global hub for preclinical CRO services.

Asia Pacific Preclinical CRO Market Analysis

The Asia-Pacific region is emerging as a global leader in adopting preclinical Contract Research Organizations (CROs), driven by advancements in biotechnology, innovative drug discovery, and increasing demand for cost-effective research solutions. Countries like China, India, and South Korea, along with key locations such as Singapore, have positioned themselves as hubs for preclinical outsourcing due to their robust infrastructure, skilled workforce, and favorable regulatory frameworks. For instance, The Asia-Pacific (APAC) region, driving over 50% of global clinical trials from 2017 to 2021, is rapidly adopting preclinical CROs due to lower costs, robust site availability, and streamlined regulatory processes. Enhanced growth across therapeutic areas, coupled with APAC's pharmacogenomic advantages, positions it as a leader in clinical trial innovation. Notable advantages include reduced timelines for drug development, access to advanced technologies, and the ability to leverage expertise in diverse therapeutic areas. For instance, China's integration of AI in preclinical studies has accelerated precision medicine research, while India's cost-efficient services have attracted global pharmaceutical firms. South Korea's emphasis on immuno-oncology trials exemplifies the region's focus on innovative therapeutic areas. The Asia-Pacific's strategic location also enables seamless collaboration with Western markets, ensuring its prominence as a preferred destination for preclinical CRO partnerships.

Latin America Preclinical CRO Market Analysis

Latin America is emerging as a dynamic hub for preclinical CROs due to advancements in biomedical research and innovation. Countries like Brazil, Mexico, and Argentina are leveraging state-of-the-art facilities, competitive costs, and skilled professionals to attract global collaborations. For instance, Brazil recorded 625,000 new cancer cases in 2022, yet only 2.2% of global cancer clinical trials are conducted there, driving the need for preclinical CROs to address barriers such as limited trials, regulatory delays, and resource shortages. This highlights Brazil's growing role in advancing oncology research through increased CRO adoption. Strategic positioning near North American markets enhances its appeal. Preclinical CROs in Latin America specialize in drug safety and efficacy studies, with examples like Mexican CROs excelling in toxicology and Brazilian firms leading in pharmacokinetics. These developments are positioning the region as a critical player in the global preclinical research landscape.

Middle East and Africa Preclinical CRO Market Analysis

The adoption of preclinical CROs is significantly advancing the Middle East and Africa's position in global healthcare innovation. Countries such as the UAE, Saudi Arabia, and South Africa are leveraging CRO services to streamline drug development and boost research capabilities. For instance, the Middle East's pharmaceutical market, valued at USD 36 Billion in 2023, is fostering preclinical CRO adoption, driven by rising investments in drug development and regulatory demands. This growth highlights the region's increasing focus on advanced research services to meet expanding healthcare needs. These advancements reduce costs and accelerate timelines, fostering a competitive edge. Key hubs like Dubai and Cape Town are becoming research centers due to infrastructure investments and collaborations. This strategic approach is strengthening the region's role in global clinical research and pharmaceutical innovation.

Competitive Landscape:

The global preclinical CRO market is characterized by intense competition, driven by the growing demand for specialized services and the increasing trend of outsourcing drug development. Leading players dominate the market with comprehensive service portfolios, advanced technological capabilities, and global footprints. These companies invest heavily in research and development, strategic partnerships, and acquisitions to expand their offerings and stay ahead in the competitive landscape. Smaller and mid-sized CROs are also gaining traction by focusing on niche services, cost-effectiveness, and flexibility in client engagement. The market sees innovation as a key competitive factor, with companies adopting AI, predictive analytics, and automated platforms to improve efficiency and accuracy. Regional players are expanding their presence in emerging markets like Asia-Pacific, further intensifying the competition. The industry's growth potential continues to attract new entrants, adding to the dynamic and competitive nature of the market.

The report provides a comprehensive analysis of the competitive landscape in the preclinical CRO market with detailed profiles of all major companies, including:

  • Charles River Laboratories Inc.
  • Covance Inc. (Laboratory Corporation of America Holdings)
  • Eurofins Scientific
  • ICON Plc
  • MD Biosciences Inc. (MLM Medical Labs)
  • Medpace
  • Parexel International Corporation
  • PPD Inc.
  • Wuxi AppTec

Key Questions Answered in This Report

  • 1.What is preclinical CRO?
  • 2.How big is the preclinical CRO market?
  • 3.What is the expected growth rate of the global preclinical CRO market during 2025-2033?
  • 4.What are the key factors driving the market?
  • 5.What is the leading segment of the global preclinical CRO market based on service?
  • 6.What is the leading segment of the global preclinical CRO market based on end use?
  • 7.What are the key regions in the global preclinical CRO market?
  • 8.Who are the key players/companies in the global preclinical CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Preclinical CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Service

  • 6.1 Bioanalysis and DMPK Studies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Toxicology Testing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End Use

  • 7.1 Biopharmaceutical Companies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Government and Academic Institutes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Medical Device Companies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Charles River Laboratories Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Covance Inc. (Laboratory Corporation of America Holdings)
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 SWOT Analysis
    • 13.3.3 Eurofins Scientific
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 ICON Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 MD Biosciences Inc. (MLM Medical Labs)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Medpace
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Parexel International Corporation
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 SWOT Analysis
    • 13.3.8 PPD Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Wuxi AppTec
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials

List of Figures

  • Figure 1: Global: Preclinical CRO Market: Major Drivers and Challenges
  • Figure 2: Global: Preclinical CRO Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Preclinical CRO Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Preclinical CRO Market: Breakup by Service (in %), 2024
  • Figure 5: Global: Preclinical CRO Market: Breakup by End Use (in %), 2024
  • Figure 6: Global: Preclinical CRO Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Preclinical CRO (Bioanalysis and DMPK Studies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Preclinical CRO (Bioanalysis and DMPK Studies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Preclinical CRO (Toxicology Testing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Preclinical CRO (Toxicology Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Preclinical CRO (Other Services) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Preclinical CRO (Other Services) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Preclinical CRO (Biopharmaceutical Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Preclinical CRO (Biopharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Preclinical CRO (Government and Academic Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Preclinical CRO (Government and Academic Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Preclinical CRO (Medical Device Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Preclinical CRO (Medical Device Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: North America: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: North America: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: United States: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: United States: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Canada: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Canada: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Asia-Pacific: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Asia-Pacific: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: China: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: China: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Japan: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Japan: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: India: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: India: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: South Korea: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: South Korea: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Australia: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Australia: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Indonesia: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Indonesia: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Others: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Others: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Europe: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Europe: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Germany: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Germany: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: France: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: France: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United Kingdom: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United Kingdom: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Italy: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Italy: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Spain: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Spain: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Russia: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Russia: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Latin America: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Latin America: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Brazil: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Brazil: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Mexico: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Mexico: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Middle East and Africa: Preclinical CRO Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Middle East and Africa: Preclinical CRO Market: Breakup by Country (in %), 2024
  • Figure 67: Middle East and Africa: Preclinical CRO Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Global: Preclinical CRO Industry: SWOT Analysis
  • Figure 69: Global: Preclinical CRO Industry: Value Chain Analysis
  • Figure 70: Global: Preclinical CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Preclinical CRO Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Preclinical CRO Market Forecast: Breakup by Service (in Million USD), 2025-2033
  • Table 3: Global: Preclinical CRO Market Forecast: Breakup by End Use (in Million USD), 2025-2033
  • Table 4: Global: Preclinical CRO Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Preclinical CRO Market: Competitive Structure
  • Table 6: Global: Preclinical CRO Market: Key Players